CTRI/2011/06/001841暂停未知
A Randomized, Prospective, Parallel, Single Centre, Open label, Comparative, Effectiveness and Safety study of Fixed dose combination [FDC] of Triple Oral Therapy of Glimepiride 2mg + Metformin 500 mg SR + Pioglitazone 15mg Vs Insulin 70/30 Mix Metformin 500mg SR treatment in insulin-naïve patients with type 2 diabetes inadequately controlled on dual, Glimepiride 1 / 2 mg + Metformin 500 mg therapy (HbA1c more than 8%)
试验速览
- 阶段
- 未知
- 状态
- 暂停
- 入组人数
- 70
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •Subjects meeting all of the following criteria will be considered for enrollment into the study
- •-Subjects or their legally-acceptable representatives (LARs) must sign an informed consent document indicating that they understand the purpose of and procedures required for the study and are willing to participate in the study.
- •-18 years of age, upper limit at the discretion of Investigator.
- •-Patients diagnosed of type 2 diabetes as defined by the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus (Appendix A) at least 6months prior to screening.
- •-HbA1C greater than 8%
- •-Insulin naive
- •-Patients who are either not receiving or are on a constant dose of lipid lowering agent/s since last three months.
- •-Patients with stable dietary and exercise pattern since three months and willing to follow the same for the entire trial duration.
- •(There is no upper limit to age)
排除标准
- •-Stroke, myocardial infarction, coronary artery bypass graft, percutaneous transluminal coronary angioplasty, or angina pectoris, within the last 12 months
- •Cardiac status New York Heart Association (NYHA) III-IV
- •Impaired renal function as shown by, but not limited to, serum creatinine more than or equal to 1.5 mg/dL for males, more than or equal to 1.4 mg/dL for females
- •Use of Oral hypoglycemic agent in the past 3 months
- •Acute infection
- •Clinically significant peripheral edema
- •Acute or chronic history of metabolic acidosis, including diabetic ketoacidosis
- •Clinical evidence of active liver disease, or serum alanine aminotransferase (ALT) or aspartate aminotransferase (AST) 2.5 times the upper limit of the normal range
- •History of hypoglycemia unawareness
- •Pregnancy or lactation
- •Known hypersensitivity to any Oral hypoglycemic agent.
- •Any malignancy within the last 5 years, with the exception of adequately treated
- •basal or squamous cell carcinoma of the skin or adequately treated cervical carcinoma in situ
- •Current addiction or current alcohol abuse, or history of substance or alcohol abuse within the last 2 years
- •Diagnosis of dementia
- •Subject is the investigator or any sub-investigator, research assistant, pharmacist, study coordinator, other staff or relative thereof directly involved in the conduct of the protocol
- •Mental condition rendering the subject unable to understand the nature, scope, and possible consequences of the study. Subject unlikely to comply with protocol, e.g., uncooperative attitude, inability to return for follow-up visits, and unlikelihood of completing the study
- •Indications of Insulin in Type 2 Diabetes
- •At onset, if FBG is 250 mg/dl and/or ketonuria. In stressful situations (acute myocardial infarction, stroke, fulminant infections, trauma). During pregnancy. Perioperative state. Hepatic and renal decompensation. Diabetic coma Idiosyncrasies to oral anti-diabetic agents. Secondary failure to OHA. Diabetics on steroids
- •Any disease or condition that in the opinion of the investigator and/or sponsor may interfere with the completion of the study
研究者
相似试验
招募中
不适用
Effect of Renexin tablet in patients with recurrent vestibulopathyKCT0000987Asan Medical Center60
已完成
1 期
Study of efficacy and safety of KSM-66 Ashwagandhaa (Withania somnifera Dunal) in stress and anxiety and on general well being in healthy adults.CTRI/2011/091/000222Ixoreal Biomed Priavte Limited,#5-9-225, 3rd floor, Sanali estate, Chirag ali lane, Abids,Hyderabad, Andhra Pradesh- 500001, India60
招募中
不适用
SODIUM BICARBONATE AND CHRONIC KIDNEY DISEASE PROGRESSIOCTRI/2022/02/039964INSTITUTE OF POST GRADUATE MEDICAL EDUCATION AND RESEARCH KOLKATA
已完成
3 期
A Prospective Randomized Single Centre Parallel Design Controlled Study to Evaluate The Efficacy and Safety of DNANOSTANNA, In The treatment of (Triple Negative/HER-2 Negative) Stage III A Or III B Breast CancerCTRI/2018/02/011707Dhanvantari Nano Ayushadi Private Limited6
进行中（未招募）
1 期
Clinical research study to determine how trazodone can influence the sleep and how it works in the body after one or repeated doses taken by mouth, in children suffering from insomnia and with autism, intellectual disability or attention deficit hyperactivity disorder (ADHD)Insomnia in children and adolescents with autism, intellectual disability or ADHDMedDRA version: 20.0Level: PTClassification code 10022443Term: Insomnia related to another mental conditionSystem Organ Class: 10037175 - Psychiatric disordersEUCTR2018-001166-42-ESAziende Chimiche Riunite Angelini Francesco ACRAF S.p.A (Angelini S.p.A.)36